2025 United Kingdom Cancer Vaccine Market Revenue Opportunities Report
Description
The 2025 United Kingdom Cancer Vaccine Market Revenue Opportunities Report features 1) market size data for the region or country, 2) annual market growth rates, 3) the market's impact on related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing, 4) Total Addressable Market (TOM) for the four largest market players, 5) Serviceable Addressable Market (SAM), and 6) Serviceable Obtainable Market (SOM)(Wharry Sharpe Research)
The Revenue Opportunities Reports provide market size data for a three-year historical trend (2019-2022), a three-year forecast estimate trends (2023-2025), and a five-year outlook projection (2026-2031) for the region or country. The report also features written analysis on market definitions, and market segments.
Market and product shipments include the total value of all products produced and shipped by all producers (also described as value of receipts, value of production, or value of work done.)
The report features written analysis and market size statistics on opportunities created in the Cancer Vaccine Market by the changing related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing,
The four largest companies actively participating in the cancer vaccine market in the United Kingdom are AstraZeneca, GlaxoSmithKline (GSK), Merck & Co., and Scancell. AstraZeneca, headquartered in Cambridge, UK, is a multinational pharmaceutical giant with a strong oncology portfolio and advanced research centers focusing on cancer vaccines and therapies. GSK, based in London, is a major global vaccine player with innovations in immunisation, including cancer-related vaccines. Merck & Co., though headquartered in the US, holds significant presence and activities in the UK market with its research-driven approach and cancer vaccine development. Scancell is a UK-based biotech specializing specifically in cancer vaccines; its lead candidate SCIB1/iSCIB1+ is in phase 2 clinical trials for advanced melanoma, showing promising disease control rates and significant recent funding.
Together, these companies drive substantial research and commercialization efforts in the UK cancer vaccine market, which is projected to nearly double in revenue from USD 349.1 million in 2023 to USD 666.3 million by 2030, at a CAGR of 9.7%. AstraZeneca leverages acquisitions and biotech innovation to enhance oncology treatment platforms, while Scancell focuses on novel immunotherapies targeting T cell responses against tumors. GSK and Merck contribute with broad vaccine expertise and pipelines that include preventive and therapeutic cancer vaccines. This dynamic participation highlights the UK's strategic role in advancing cancer vaccine technologies amid a growing market landscape.
Revenue Opportunities are defined by the measurements of Total Addressable Market (TOM) for the four largest market players, Serviceable Addressable Market (SAM), and Serviceable Obtainable Market (SOM). The measurements include both written analysis and current calculations for each company in the market for each country or region.
This report does not provide the names of companies in the market or written analysis of each market's trends within each country to provide a cost-effective report that focuses solely on the statistics and data on each market.
Wharry Sharpe Research publishes thousands of market analysis and product research report annually to assist their clients with the essential data they need for the market research, budgeting and forecasting needs.
The Revenue Opportunities Reports provide market size data for a three-year historical trend (2019-2022), a three-year forecast estimate trends (2023-2025), and a five-year outlook projection (2026-2031) for the region or country. The report also features written analysis on market definitions, and market segments.
Market and product shipments include the total value of all products produced and shipped by all producers (also described as value of receipts, value of production, or value of work done.)
The report features written analysis and market size statistics on opportunities created in the Cancer Vaccine Market by the changing related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing,
The four largest companies actively participating in the cancer vaccine market in the United Kingdom are AstraZeneca, GlaxoSmithKline (GSK), Merck & Co., and Scancell. AstraZeneca, headquartered in Cambridge, UK, is a multinational pharmaceutical giant with a strong oncology portfolio and advanced research centers focusing on cancer vaccines and therapies. GSK, based in London, is a major global vaccine player with innovations in immunisation, including cancer-related vaccines. Merck & Co., though headquartered in the US, holds significant presence and activities in the UK market with its research-driven approach and cancer vaccine development. Scancell is a UK-based biotech specializing specifically in cancer vaccines; its lead candidate SCIB1/iSCIB1+ is in phase 2 clinical trials for advanced melanoma, showing promising disease control rates and significant recent funding.
Together, these companies drive substantial research and commercialization efforts in the UK cancer vaccine market, which is projected to nearly double in revenue from USD 349.1 million in 2023 to USD 666.3 million by 2030, at a CAGR of 9.7%. AstraZeneca leverages acquisitions and biotech innovation to enhance oncology treatment platforms, while Scancell focuses on novel immunotherapies targeting T cell responses against tumors. GSK and Merck contribute with broad vaccine expertise and pipelines that include preventive and therapeutic cancer vaccines. This dynamic participation highlights the UK's strategic role in advancing cancer vaccine technologies amid a growing market landscape.
Revenue Opportunities are defined by the measurements of Total Addressable Market (TOM) for the four largest market players, Serviceable Addressable Market (SAM), and Serviceable Obtainable Market (SOM). The measurements include both written analysis and current calculations for each company in the market for each country or region.
This report does not provide the names of companies in the market or written analysis of each market's trends within each country to provide a cost-effective report that focuses solely on the statistics and data on each market.
Wharry Sharpe Research publishes thousands of market analysis and product research report annually to assist their clients with the essential data they need for the market research, budgeting and forecasting needs.
Table of Contents
51 Pages
- A. Definitions
- A1. Market Definition
- A2. Market Segmentation
- A3. Industry Opportunities-Industry1
- A4. Industry Opportunities-Industry2
- A5. Industry Opportunities-Industry3
- B. Total Addressable Market (TAM)
- B1. TAM-Player 1/4
- B2. TAM-Player 2/4
- B3. TAM-Player 3/4
- B4. TAM-Player 4/4
- C. Serviceable Addressable Market (SAM)
- C1. SAM-Player 1/4
- C2. SAM-Player 2/4
- C3. SAM-Player 3/4
- C4. SAM-Player 4/4
- D. Serviceable Obtainable Market (SOM)
- D1. SOM-Player 1/4
- D2. SOM-Player 2/4
- D3. SOM-Player 3/4
- D4. SOM-Player 4/4
- E. Appendix
Search Inside Report
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
